Fei-Ting (Doris) Hsu received her Ph.D. in Biomedical Imaging and Radiological Sciences in 2014 from the National Yang-Ming University, Taipei, Taiwan under the mentorship of Prof. Jeng-Jong Hwang. Her thesis works examined the synergistic effect of sorafenib combines with radiation or vorinostat on human hepatocellular carcinoma is via inhibition of ERK/NF-kappa B signalling pathway. Dr. Hsu research interested is mainly focussing on cancer therapy strategy design and identification of molecular mechanism in tumor microenvironment. Dr. Hsu majors in tumor biology, tumor immunology, molecular image, translation medicine, theranostic probe, and radiobiology. In 2008, she joined an exchange student program in Prof. Lydia Su and Prof. Jeon-Hor Chen lab, Center for Functional Onco-Imaging, School of Medicine, University of California Irvine, Irvine, CA, USA. Dr. Hsu was trained as Postdoctoral and Medical Physicist in Taipei Medical University/Hospital and received Assistant Professor certification in 2017.

Dr. Hsu is currently an Associate Professor at Department of Biological Science and Technology at China Medical University, Taichung, Taiwan. Our group is currently working on establishing new therapeutic drugs for glioblastoma, hepatocellular carcinoma, non-small cell lung cancer. We believe these researchs will be helpful in the comprehensive understanding of glioblastoma and may lead to a better disease management.

​

​

ORCID: https://orcid.org/0000-0002-2153-340X